@article{Marziali_Isgrò_Gaziev_Lucarelli_2009, title={HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA AND SICKLE CELL DISEASE: EXPERIENCE OF MEDITERRANEAN INSTITUTE OF HEMATOLOGY IN A MULTI-ETHNIC POPULATION.}, volume={1}, url={https://www.mjhid.org/mjhid/article/view/2009.027}, abstractNote={<p class="Heading31" style="line-height: 150%; margin: 8.5pt 0cm 2.5pt;"><span style="font-family: Times;"><span style="line-height: 150%; font-size: 12pt; font-weight: normal;" lang="EN-US">Hematopoietic stem cell transplantation</span><span style="line-height: 150%; font-size: 12pt; font-weight: normal; mso-ansi-language: EN;" lang="EN-US"> </span><span style="line-height: 150%; font-size: 12pt; font-weight: normal; mso-ansi-language: EN;" lang="EN">(HSCT) still remains the only definitive cure currently available for patients with thalassemia and sickle cell anemia.<span style="mso-spacerun: yes;">  </span>Results of transplant in thalassemia<span style="mso-spacerun: yes;">  </span>and in sickle cell anemia<span style="mso-spacerun: yes;">  </span>have steadily improved over the last two decades due to improvements in preventive strategies, and effective control of transplant-related complications.</span><span style="line-height: 150%; font-size: 12pt; font-weight: normal;" lang="EN-US"> From 2004 through<span style="mso-spacerun: yes;">  </span>2009,<span style="mso-spacerun: yes;">  </span>145 consecutive patients </span><span style="line-height: 150%; font-size: 12pt; font-weight: normal; mso-ansi-language: EN;" lang="EN">with thalassemia and sickle cell anemia, </span><span style="line-height: 150%; font-size: 12pt; font-weight: normal;" lang="EN-US">ethnically heterogeneous from Mediterranean and Middle East countries, were given HSCT in the International Center for Transplantation in Thalassemia and Sickle Cella Anemia in Rome. This experience is characterized by two peculiarities: patients were ethnically very heterogeneous and the vast majority of these patients were not regularly transfesed/chelated and therefore were highly sensitized due to RBC transfusions without leukodepletion filters. Consequently, they could have a high risk of graft rejection as a result of sensitization to HLA antigens. The Rome experience of SCT in patients with thalassemia </span><span style="line-height: 150%; font-size: 12pt; font-weight: normal; mso-ansi-language: EN;" lang="EN">and sickle cell anemia</span><span style="line-height: 150%; font-size: 12pt; font-weight: normal;" lang="EN-US"> confirmed the results obtained in Pesaro, and most importantly showed the reproducibility of these results in other centers. </span></span></p><p class="MsoNormal" style="margin: 0cm 0cm 0pt;"><span style="mso-ansi-language: EN-US;" lang="EN-US"><span style="font-family: Times New Roman; font-size: small;"> </span></span></p>}, number={1}, journal={Mediterranean Journal of Hematology and Infectious Diseases}, author={Marziali, Marco and Isgrò, Antonella and Gaziev, Javid and Lucarelli, Guido}, year={2009}, month={Dec.}, pages={e2009027} }